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Natriuretic Peptides and Neprilysin*
Allan S. Jaffe, MDN atriuretic peptides are an important aid forthe diagnosis of heart failure (HF) and mayallow for the monitoring of therapy in pa-
tients with HF over time. One view often taken to
simplify their use is that elevated values reﬂect a
more exuberant counterregulatory response to hemo-
dynamic stress, such that these elevated levels are
therefore indicative of the severity of HF and thus
reﬂect prognosis.
However, it has been clear from a variety of studies
that the natriuretic peptide system is far more com-
plex. It is highly dysfunctional in HF; in many of
these patients, it is difﬁcult to detect signiﬁcant
quantities of bioactive B-type natriuretic peptide
(BNP) 1-32 (1). Much of the BNP measured by
contemporary assays is either nonprocessed proBNP
or degradation products of BNP 1-32, such as BNP
3-32, BNP 5-32, and BNP 8-32 (1). The reasons for this
have recently begun to be appreciated. ProBNP,
which contains 108 amino acids, needs to be cleaved
into constituents (a presumably inert N-terminal
proBNP [NT-proBNP] fragment and active BNP 1-32),
and that requires not only convertases such as corin
(a transmembrane and soluble protease) and furin (an
intercellular endopeptidase) but also the lack of
glycosylation (or deglycosylation) of proBNP at amino
acid 71 (threonine; i.e., T71). In the case of glycosyl-
ation at T71, it appears that proBNP processing is
inhibited, and for that reason, more proBNP may be
generated. ProBNP is much less potent in stimulating*Editorials published in the Journal of the American College of Cardiology
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theheart.org.the second messengers responsible for the biological
effects of natriuretic peptides. In acute HF, the
greater plasma levels of natriuretic peptides are
associated with a greater rate of deglycosylation,
which leads to more effect of the natriuretic peptides.
This may also be the reason values are more labile and
increase and decrease more rapidly as the system
adjusts. In more chronic HF, deglycosylation is less
robust, and consequently, there is more proBNP and
less BNP 1-32, and values, once elevated, take longer
to become reduced in response to therapy (2).
Into this space come the recent provocative data
regarding use of LCZ696, a combination neprilysin
inhibitor and angiotensin receptor blocker. The
PARADIGM-HF trial (Prospective Comparison of ARNI
With ACEI to Determine Impact on Global Mortality
and Morbidity in Heart Failure) demonstrated marked
improvement in outcomes with LCZ696 compared
with enalapril alone in patients with predominantly
New York Heart Association functional class II HF (3).
Because neprilysin is responsible, in part, for
degrading natriuretic peptides, one view might be
that by inhibiting natriuretic peptide degradation,
one improves the level of BNP 1-32 and, by doing so,
improves HF. But the realities of BNP processing
presented as just discussed suggest that it is probably
not that simple. Given the profound abnormalities of
the natriuretic peptide system and its dependence on
deglycosylation, it is likely that additional effects of
neprilysin or angiotensin receptor blockers must be
present to affect HF in any substantial way.SEE PAGE 657The paper in this issue of the Journal from Bayés-
Genís et al. (4) adds to our knowledge in this area.
What they suggest is that measurement of neprilysin
concentrations with an assay that appears reason-
ably speciﬁc holds prognostic importance. Specif-
ically, this suggests that the neprilysin concentration
in and of itself is an important prognostic factor.
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667Levels manifested both incremental value and sub-
stantially improved calibration and reclassiﬁcation.
They maintained those attributes even when high-
sensitivity cardiac troponin T, NT-proBNP, esti-
mated glomerular ﬁltration rate, and ST2 were added
to the model. Unfortunately, this evaluation was
based only on a single baseline sample, a common
practice, but to this investigator a major limitation.
Additionally, in a cohort designed tomatch the clinical
characteristics of the PARADIGM-HF cohort, baseline
neprilysin levels were signiﬁcantly associated with the
primary endpoint of cardiovascular death or HF hos-
pitalization but not cardiovascular death alone or all-
cause mortality. However, in patients who had more
normal ejection fractions, recognizing that analyses of
subsets induce smaller sample sizes, neprilysin con-
centration was associated with both the composite
endpoint and HF hospitalizations, as well as cardio-
vascular death.
Howmight this all work? The simplistic view that by
inhibiting neprilysin one is increasing BNP 1-32 may or
may not be correct. Indeed, levels could go down
because more functional natriuretic peptide is circu-
lating. Perhaps neprilysin interacts with the deglyco-
sylation process or changes the relative activity or
efﬁcacy of furin and corin, the convertases essential for
cleaving proBNP into BNP 1-32 and the NT-proBNP
fragment. On the other hand, BNP values also could
diminish if other mechanisms of beneﬁt, which could
be independent of natriuretic peptides, lead to im-
provement in HF. It is known that neprilysin causes
proteolysis not only of natriuretic peptides but also of a
variety of components that are essential in the mech-
anisms of action for several other circulating hor-
mones, such as adrenomedullin, atrial natriuretic
peptide, bradykinins, angiotensin I, endothelin-1, and
substance P (5). Any or all of these effects couldmodify
HF severity and progression, and there may be other
analytes that also are involved. Thus, it could be that
neprilysin has a great deal to do with natriuretic pep-
tide homeostasis or very little to do with natriuretic
homeostasis as a primary mechanism of its effect.Either way, a major paradigm shift has occurred in
the cardiovascular realm. We now have a new agent
in LCZ696 that is capable of reducing mortality and
hospitalizations via mechanisms that are not yet
totally understood. We already know that there are
differences in the processing of natriuretic peptides
between patients with acutely decompensated HF
and those with chronic HF (2). Could it be that end-
stage HF is different still? There are some sugges-
tions that could be the case (6). If so, the impact of
neprilysin on the natriuretic peptide system may vary
by subset.
Nonetheless, the ability to add measurements of
neprilysin concentrations to ongoing research ef-
forts may enrich our understanding of these mech-
anisms and allow us to better leverage this approach
to help patients with HF. At present, the assay used
is not one that would be easy to implement clini-
cally, and although it adds prognostic signiﬁcance,
it remains unclear whether the incremental value is
robust enough to warrant routine use. Furthermore,
it would be of interest to assess neprilysin activity,
because it is known that the convertases can change
activity without a recognizable change in mass
concentration (2). In the interim, the proposition
that neprilysin is important remains and suggests
that for research studies, its inclusion in multivar-
iate models that examine prognosis may be illumi-
nating. The bigger hope is that future studies using
serial samples will permit assessment of patient
response to various treatments as part of efforts to
improve our understanding of the basic mechanisms
of neprilysin inhibition. In the long run, such un-
derstanding will allow further improvements in
drug development based on this promising new
therapy.
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